The Food and Drug Administration has approved the use of a fourth COVID-19 vaccine and booster from Novavax! The Novavax vaccine is 90% effective against mild to moderate cases of COVID-19. Using a traditional protein-based vaccine that uses only part of the virus that is delivered directly to the cells, Novavax differs from the mRNA approach taken by Pfizer-BioNTech, Moderna, and Johnson and Johnson. All Individuals ages 12 and older are eligible for the two shot primary series, and can get the second shot three to eight weeks after their initial vaccine.
In October 2022, the FDA approved the Novavax booster for individuals ages 18 and older, although it may not be as effective in protecting against newer variants of COVID-19. The protein-based vaccine allows individuals who weren’t able to get the other vaccines due to health conditions the opportunity to get vaccinated. Looking to get the Novavax vaccine, or other COVID-19 vaccines? Check out vaccines.gov for COVID-19 vaccines, boosters, and flu shots near you!